Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiaggregant treatment: present and future].

C S Kase1

  • 1Departamento de Neurología, Universidad de Boston, Massachusetts 02118, USA. cskase@bu.edu

Revista De Neurologia
|July 23, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers and functional outcomes from ischaemic cerebral events in women: a prospective cohort study.

European journal of neurology·2012
Same author

Advances in intracerebral haemorrhage management.

European journal of anaesthesiology. Supplement·2008
Same author

Lipid levels and the risk of ischemic stroke in women.

Neurology·2007
Same author

Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men.

Neurology·2006
Same author

Migraine, headache, and the risk of stroke in women: a prospective study.

Neurology·2005
Same author

Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study.

Neurology·2004

Antiplatelet medications like aspirin help prevent strokes by reducing blood clot formation. Future treatments may combine these agents with antithrombotics and neuroprotectants for enhanced cerebrovascular accident prevention.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Antiplatelet agents are crucial in preventing cerebrovascular accidents (CVA).
  • Aspirin is a standard treatment for TIA and minor CVA, reducing risk by 20%.
  • Newer agents offer improved efficacy and safety profiles.

Purpose of the Study:

  • To review current antiplatelet therapies for CVA prevention.
  • To explore future directions in antiplatelet treatment development.

Main Methods:

  • Review of established antiplatelet drugs: Aspirin, Ticlopidine, Dipyridamole, and Clopidogrel.
  • Analysis of combination therapies, including Aspirin with Dipyridamole and Aspirin with heparin.
  • Evaluation of drug efficacy, side effects, and specific indications (e.g., coronary stent patency).

Related Experiment Videos

Main Results:

  • Aspirin alone reduces CVA risk by 20%.
  • Combination therapy with Aspirin and Dipyridamole shows a 37% risk reduction.
  • Clopidogrel offers comparable efficacy to Ticlopidine with fewer hematologic side effects.
  • Combination therapy with Aspirin and subcutaneous heparin is effective in early secondary CVA prevention.

Conclusions:

  • Antiplatelet agents represent a significant advancement in CVA management.
  • Future strategies likely involve combining Aspirin with other antiplatelet drugs, antithrombotics, and neuroprotective agents for improved outcomes.